Hjem › Nyrekreft (nyrecellekarcinom) › Massachusetts › Boston
Kliniske studier for Nyrekreft (nyrecellekarcinom) i Boston, MA
16 studier for Nyrekreft (nyrecellekarcinom) søker deltakere på steder i og rundt Boston (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
RekruttererFase 1
- Research Site, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
RekruttererFase 1
- Exelixis Clinical Site #7, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
RekruttererFase 1/2
- Tufts Medical Center, Boston
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
RekruttererFase 2
- Massachusetts General Hospital Cancer Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RekruttererFase 1/2
- Brigham and Women's Hospital, Boston
- Dana Farber/Mass General Brigham Cancer Care, Inc, Boston
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
RekruttererFase 3
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sasanlimab, Palbociclib and Axitinib in Metastatic Renal Cell Carcinoma
RekruttererFase 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study of DCC-2812 in Participants With Advanced Genitourinary Cancers
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
RekruttererFase 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Renal Cell Carcinoma
RekruttererFase 1
- Dana-Farber Cancer Institute, Boston
Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC
RekruttererFase 2
- Beth Israel Deaconess Medical Center, Boston
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RekruttererFase 1/2
- Massachusetts General Hospital, Boston
Nyrekreft (nyrecellekarcinom)-studier i andre byer
- Houston, TX35 studier
- New York City, NY27 studier
- Nashville, TN23 studier
- Dallas, TX23 studier
- St. Louis, MO23 studier
- Los Angeles, CA20 studier
- Baldwin Park, CA16 studier
- Philadelphia, PA15 studier
- Pittsburgh, PA15 studier
- Queens, NY15 studier
- Rochester, MN14 studier
- Cleveland, OH14 studier
Andre studier i Boston
- Brystkreft112 studier
- Ikke-småcellet lungekreft90 studier
- Kreft (alle typer)85 studier
- Metastatisk kreft63 studier
- Kolorektal kreft63 studier
- Lungekreft62 studier
- Eggstokkreft61 studier
- Prostatakreft59 studier
- Depresjon52 studier
- Endometriekreft50 studier
- Hjertesvikt44 studier
- Akut myelogen leukemi44 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.